FDA approved the Sapien 3 transcatheter aortic valve replacement (TAVR) platform for treatment of severe aortic stenosis ...

New analysis from the EARLY TAVR trial showed patients between the age of 65 and 70 years old derived the most benefits of a ...

Edwards’ SAPIEN 3 platform becomes the first TAVR system approved by the FDA for asymptomatic severe aortic stenosis patients ...

Edwards Lifesciences announced the FDA approved its transcatheter aortic valve replacement platform for treatment of severe ...

Edwards Lifesciences (NYSE: EW) received FDA approval for its Sapien 3 TAVR for severe aortic stenosis (AS) without symptoms.

Edwards Lifesciences (NYSE:EW) recently celebrated the FDA approval of its SAPIEN 3 TAVR therapy for asymptomatic aortic stenosis patients, a significant development in cardiac care. This milestone, ...

The agency’s decision for the balloon-expandable Sapien 3 platform is based on groundbreaking results from EARLY TAVR.

Edwards Lifesciences has claimed a groundbreaking approval from the FDA that opens up its minimally invasive heart valve implants to patients before they begin to show cardiac symptoms.

A new method of alerting clinical care providers holds promise for increasing treatment and improving survival for patients with severe aortic stenosis (AS), a valvular heart condition that can be ...

The FDA approved Edwards Lifesciences Corp.'s Sapien 3 platform for patients with asymptomatic severe aortic stenosis.